Investment Rating - The report maintains a "Buy" rating for JD Logistics with a target price of HK$23.28, representing a potential upside of 76% from the current price of HK$13.20 [1][9]. Core Insights - JD Logistics reported strong performance in 2024, with revenue growth of 9.7% and a significant increase in adjusted net profit by 187%, exceeding management's initial guidance [6][7]. - Despite the strong 2024 results, management's conservative guidance for 2025 suggests low double-digit revenue growth and single-digit adjusted net profit growth, which has led to market dissatisfaction and a subsequent drop in stock price [7][8]. - The current valuation of JD Logistics appears attractive, trading at 10.6 times the 2025 P/E ratio, which is lower compared to peers in the logistics sector [8][15]. Summary by Sections Investment Rating - The investment rating remains "Buy" with a target price adjustment from HK$22.90 to HK$23.28, reflecting a 2% increase [2][9]. Financial Performance - Revenue for 2024 reached RMB 182,838 million, with a projected revenue of RMB 205,510 million for 2025, indicating a growth rate of 12.4% [10][20]. - Adjusted net profit for 2024 was RMB 6,867 million, with expectations of RMB 7,353 million for 2025, marking a 7.1% increase [10][20]. Earnings Forecast - The report adjusts the earnings per share (EPS) estimates for 2025 to RMB 1.18, up from RMB 1.07, reflecting a 10% increase [2][14]. - The adjusted net profit margin is projected to be 3.6% for 2025, slightly improving from previous estimates [14][20]. Valuation - The DCF model indicates a target price of HK$23.28, with a WACC of 12.1% and a perpetual growth rate of 2% [15][16]. - The current stock price implies a significant discount compared to the target price, suggesting limited downside risk [8][15].

Investment Rating - The report maintains a "Buy" rating for JD Logistics with a target price of HK$23.28, representing a potential upside of 76% from the current price of HK$13.20 [1][9]. Core Insights - JD Logistics reported strong performance in 2024, with revenue growth of 9.7% and a significant increase in adjusted net profit by 187%, exceeding management's initial guidance [6][7]. - Despite the strong 2024 results, management's conservative guidance for 2025 suggests low double-digit revenue growth and single-digit adjusted net profit growth, which has led to market dissatisfaction and a subsequent drop in stock price [7][8]. - The current valuation of JD Logistics appears attractive, trading at 10.6 times the 2025 P/E ratio, which is lower compared to peers in the logistics sector [8][15]. Financial Performance Summary - Revenue for 2024 was RMB 182,838 million, with a projected revenue of RMB 205,510 million for 2025, reflecting a growth rate of 12.4% [10][20]. - Adjusted net profit for 2024 was RMB 6,867 million, with an expected increase to RMB 7,353 million in 2025, indicating a growth of 7.1% [10][20]. - The gross profit margin improved from 7.6% in 2023 to 10.2% in 2024, with a projected margin of 10.7% for 2025 [10][20]. Earnings Forecast Adjustments - The report has adjusted the earnings forecasts for 2025 and 2026, increasing revenue estimates by 7.3% and 9.0% respectively, based on the strong performance in 2024 [13][14]. - The adjusted EPS for 2025 is now projected at RMB 1.18, up from RMB 1.07, reflecting a 10.5% increase [14][15]. Valuation Analysis - The target price of HK$23.28 is based on a discounted cash flow (DCF) model, maintaining a WACC of 12.1% and a perpetual growth rate of 2% [15][16]. - The current stock price is seen as having limited downside potential due to the conservative guidance and low market expectations [8][9].

Investment Rating - The report maintains a "Buy" rating for JD Health with a target price of HK$55.17, representing a potential upside of 54% from the current price of HK$35.75 [2][15]. Core Insights - JD Health's revenue for 2024 is projected to be RMB 58.16 billion, reflecting an 8.6% year-on-year growth, with a significant profit increase of 94% to RMB 4.16 billion [6][9]. - The company is expected to continue optimizing its product mix, leading to a gross profit increase to RMB 13.31 billion in 2024, up 12.2% [6]. - The report highlights the robust growth in product sales and the optimization of the omnichannel layout, with product sales revenue expected to grow at a compound annual growth rate (CAGR) of 15% from 2025 to 2027 [7]. - JD Health is expanding its healthcare service ecosystem, with service revenue projected to grow at a CAGR of 17% from 2025 to 2027 [8]. Financial Summary - The financial data indicates that JD Health's revenue is expected to reach RMB 67.09 billion in 2025, with a gross profit of RMB 15.86 billion and a net profit of RMB 4.53 billion [9][21]. - The adjusted EPS for 2025 is projected at RMB 1.41, with a growth trajectory leading to RMB 1.97 by 2027 [9][12]. - The report notes a significant increase in operating efficiency, with operating profit expected to rise by 132.9% in 2024 [6][10]. Valuation - The DCF valuation method used in the report results in a target price of HK$55.17, which is based on a WACC of 9.0% and a perpetual growth rate of 3.0% [15][16]. - The target price corresponds to a P/S ratio of 2.4 for 2025, which is below the industry average of 3.1, indicating potential for valuation upside [15][18].

Investment Rating - The report maintains a "Buy" rating for JD Health with a target price of HK$55.17, representing a potential upside of 54% from the current price of HK$35.75 [2][15]. Core Insights - JD Health's revenue for 2024 is projected to be RMB 58.16 billion, reflecting an 8.6% year-on-year growth, with a significant profit increase of 94% to RMB 4.16 billion [6][9]. - The company is expected to continue optimizing its product mix, leading to a gross profit increase to RMB 13.31 billion, a 12.2% rise [6]. - The report highlights the robust growth in service revenue, with expectations of a 17% year-on-year increase from 2025 to 2027 [8]. Financial Summary - **Revenue Projections**: - 2025E: RMB 67.09 billion - 2026E: RMB 77.22 billion - 2027E: RMB 87.60 billion [9][12] - **Gross Profit Projections**: - 2025E: RMB 15.86 billion - 2026E: RMB 18.25 billion - 2027E: RMB 20.79 billion [9][12] - **Net Profit Projections**: - 2025E: RMB 4.53 billion - 2026E: RMB 5.34 billion - 2027E: RMB 6.30 billion [9][12] - **Earnings Per Share (EPS)**: - 2025E: RMB 1.41 - 2026E: RMB 1.67 - 2027E: RMB 1.97 [9][12] Market Comparison - JD Health's target price corresponds to a price-to-sales (P/S) ratio of 2.4 times for 2025, which is below the industry average of 3.1 times for comparable internet healthcare platforms [15][18].

Investment Rating - The investment rating for Anta Sports is "Buy" with a target price of HK$110.40, representing a potential upside of 16% from the current price of HK$95.10 [1][8]. Core Views - The report maintains the earnings forecast and "Buy" rating, raising the target price by 16% to HK$110.40, corresponding to a 19 times P/E for 2026 [8]. - Revenue and operating profit are expected to grow by 10.0% and 10.9% year-on-year in 2025, respectively, while net profit is projected to decrease slightly by 1.0% [9][8]. Summary by Sections Financial Performance - Revenue for 2025 is projected to reach RMB 770.5 billion, with a year-on-year growth of 10.0% [7][9]. - The expected earnings per share (EPS) for 2024, 2025, and 2026 are RMB 5.03, RMB 4.98, and RMB 5.46, respectively, reflecting a 1% increase for both 2024 and 2025 [2][9]. Revenue Growth Drivers - Anta brand is anticipated to achieve a revenue growth of 8.4% in 2025, driven by the expansion of Direct-to-Consumer (DTC) stores and the introduction of "super Anta" stores focusing on cost-effectiveness [7]. - FILA brand is expected to see a revenue increase of 6.4% in 2025, following adjustments in core product designs [7]. - Other brands, including Descente and KOLON, are projected to grow over 30% year-on-year in 2025 [6]. Market Position and Valuation - Anta Sports' market capitalization is approximately US$34.354 billion, with a current share count of 2,807 million [1]. - The report highlights that Anta Sports is trading at a P/E ratio of 18.0 for 2025, which is competitive compared to peers [10].

Investment Rating - The report maintains a "Buy" rating for Anta Sports with a target price of HK$110.40, indicating a potential upside of 16% from the current price of HK$95.10 [1][2]. Core Views - The report projects a revenue growth of 10% year-on-year for 2025, with operating profit expected to increase by 10.9% [5][8]. - The earnings per share (EPS) estimates for 2024, 2025, and 2026 are RMB 5.03, RMB 4.98, and RMB 5.46 respectively, reflecting slight increases from previous estimates [2][8]. Revenue and Profit Forecast - For Q1 2025, revenue is expected to grow by 5%-7% year-on-year, with Anta brand sales projected to increase significantly in January due to favorable conditions, while FILA brand sales are expected to remain flat [6][7]. - The overall revenue for Anta Sports in 2025 is forecasted to reach RMB 770.5 billion, driven by growth in various brands, including a 6.3% increase for Anta and a 6.4% increase for FILA [7][8]. Financial Summary - The financial data indicates that Anta Sports' revenue for 2024 is projected at RMB 70.049 billion, increasing to RMB 77.052 billion in 2025 and RMB 84.265 billion in 2026 [9][12]. - The net profit for 2025 is expected to be RMB 139.8 billion, a slight decrease of 1% from the previous year, with a net profit margin of 18.1% [8][9]. Valuation Metrics - The report sets a new target price based on a 19x P/E ratio for 2026, reflecting an increase of 16% from the previous target price [8][10]. - The average P/E ratio for comparable companies is noted, with Anta Sports currently at 18.0 for 2025, indicating competitive positioning within the industry [10].

Investment Rating - The report maintains a "Buy" rating for Gree Electric Appliances with a target price of RMB 51.75, indicating a potential upside of 24% from the current price of RMB 41.69 [1][2]. Core Insights - Gree is expected to have flat revenue in 2024 at RMB 204 billion, while net profit is projected to grow by approximately 12% to RMB 32.6 billion. This growth is attributed to a significant increase in air conditioning demand driven by national subsidy policies [5][8]. - The report highlights a positive signal from the increase in shareholding by the dealer platform, which suggests improved alignment of interests between Gree and its distributors. This could lead to a potential dividend payout in April 2024, with an expected dividend yield of around 6% [6][8]. - The report emphasizes that Gree's stock price has been weak, providing a better entry point for investors, especially with upcoming dividend announcements and a favorable earnings outlook for Q4 2024 and Q1 2025 [7][8]. Financial Summary - Revenue and profit forecasts for Gree Electric Appliances are as follows: - 2024E Revenue: RMB 204 billion (flat YoY) - 2025E Revenue: RMB 212 billion (4% growth YoY) - 2026E Revenue: RMB 222 billion (4.7% growth YoY) - 2024E Net Profit: RMB 32.6 billion (12.2% growth YoY) - 2025E Net Profit: RMB 34.1 billion (4.7% growth YoY) - 2026E Net Profit: RMB 36.3 billion (6.4% growth YoY) [9][10][12]. - The report maintains the earnings per share (EPS) estimates at RMB 5.81 for 2024, RMB 6.09 for 2025, and RMB 6.48 for 2026 [2][9]. Valuation Metrics - Gree's current market valuation corresponds to a P/E ratio of 8.5x for 2025, which is considered attractive compared to its peers, with Midea at 14.6x and Haier at 13.1x [7][8]. - The report notes that Gree's TTM P/E has decreased to 7.6x, which is at the lower end of its trading range over the past two and a half years [7].

Investment Rating - The report assigns a "Buy" rating to Zai Lab (ZLAB US) with a target price of US$62.32, indicating an upside potential of 80% from the current price of US$34.64 [1]. Core Insights - The company is expected to experience significant revenue growth, with a projected revenue of US$5.60-5.90 billion for 2025, following a strong performance in 2024 where revenue reached US$399 million, a 50% year-over-year increase [3][8]. - The inclusion of key products in the National Reimbursement Drug List (NRDL) has driven rapid revenue growth, particularly for Weiqijia and Weilian, which achieved sales of US$93.6 million in 2024 [4]. - The company has effectively controlled expenses, with R&D spending decreasing by 11.6% to US$235 million in 2024, contributing to improved operational efficiency [5][8]. Financial Summary - The financial projections for Zai Lab are as follows: - Revenue (US$ million): 2022A: 215, 2023A: 267, 2024E: 398, 2025E: 562, 2026E: 920 [7]. - Gross Profit (US$ million): 2022A: 141, 2023A: 171, 2024E: 259, 2025E: 364, 2026E: 593 [7]. - Net Profit (US$ million): 2022A: (443), 2023A: (334), 2024E: (307), 2025E: (205), 2026E: 22 [7]. - Earnings per Share (US$): 2022A: (4.63), 2023A: (3.42), 2024E: (3.13), 2025E: (2.10), 2026E: 0.22 [7].

Investment Rating - The report maintains a "Buy" rating for Huahong Semiconductor (1347 HK) with a target price of HK$44.00, representing a potential upside of 28% from the current price of HK$34.30 [2][9]. Core Insights - The new president, Dr. Bai Peng, has a solid background in IDM and foundry sectors, and he aims to enhance performance and efficiency by migrating some products to more advanced processes [7]. - The company is expected to benefit from the "China for China" strategy, competitive pricing compared to overseas peers, and the gradual ramp-up of its new 12-inch production line in Wuxi [7]. - The integration of Huahong's subsidiary, Huali Microelectronics, is anticipated to bring significant operational improvements and potential profit increases [7]. - Despite a slight increase in average selling prices (ASP), strong demand driven by consumer electronics is expected to continue into the first half of 2025 [8]. - Revenue forecasts for 2025 and 2026 have been adjusted downwards by 5% and 6% respectively due to pricing pressures, but the overall growth strategy remains intact [8][11]. Summary by Sections Financial Adjustments - The target price has been raised from HK$30.40 to HK$44.00, reflecting a revised P/B multiple of 1.5x for 2025 [9][13]. - The 2025E EPS has been adjusted down from US$0.12 to US$0.09, a decrease of 22% [3][11]. - Revenue estimates for 2025E and 2026E have been reduced to US$2,339 million and US$2,770 million, respectively, with year-on-year growth rates of 17% and 18% [11]. Valuation - The report emphasizes a P/B valuation approach, with the target P/B multiple increased to 1.5x, indicating a more optimistic outlook for Huahong's industry positioning and technology portfolio [13][14]. - The estimated book value per share for 2025 is projected at US$3.72, leading to a target price of HK$44.00 [14]. Market Comparison - Huahong's current P/B ratio of 1.2x is at a discount compared to its peers, such as UMC at 1.7x and SMIC at 2.5x, highlighting its valuation attractiveness [9][14].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HK$208.22, indicating a potential upside of 25% from the current price of HK$166.70 [1][6]. Core Insights - The company's revenue for 2024 is projected to reach US$3.81 billion, representing a year-on-year growth of 55.96%. The GAAP net loss is expected to narrow to US$568 million, a 53% improvement compared to the previous year [1]. - Global sales of the drug Zepzelca are anticipated to drive strong growth, with sales reaching US$2.6 billion in 2024, a 104.9% increase year-on-year. The U.S. market sales are expected to grow by 106.3% to US$2 billion, while European sales are projected to increase by 194% to US$359 million [2]. - The company is optimistic about 2025, forecasting revenue between US$4.9 billion and US$5.3 billion, a year-on-year growth of 29% to 39%, and aims to achieve operational breakeven [2]. Financial Summary - The company’s financial data for the years 2022 to 2026 shows a significant increase in revenue, with projections of US$4.9 billion in 2025 and US$5.8 billion in 2026. The gross profit is expected to rise to US$3.86 billion in 2025 [4]. - The net profit is projected to turn positive in 2025, with an expected net income of US$137 million, compared to a loss of US$554 million in 2024 [4]. - The earnings per share (EPS) is expected to improve from a loss of US$0.40 in 2024 to a profit of US$0.10 in 2025 [4].